Thursday, April 7, 2011

XenoPort nabs its first FDA approval, for restless legs syndrome

Biopharmaceutical company XenoPort Inc. CEO and co-founder Ron Barrett got the phone call he had been waiting for Wednesday: The U.S. Food and Drug Administration approved the company’s treatment of Restless Legs Syndrome.
Santa Clara-based XenoPort (NASDAQ:XNPT) and its partner in commercialization, health care group GlaxoSmithKline plc (NYSE:GSK), said the lead drug is under the trade name Horizant. Xenoport’s technology modifies an existing generic drug to help patients’ bodies better absorb it.

No comments:

Post a Comment